Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT1A receptor agonist SEP-363856
Marcus Saarinen, Ioannis Mantas, Ivana Flais, et al.
Neuropsychopharmacology (2022) Vol. 47, Iss. 13, pp. 2319-2329
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Schizophrenia: from neurochemistry to circuits, symptoms and treatments
Oliver Howes, Bernard R Bukala, Katherine Beck
Nature Reviews Neurology (2023) Vol. 20, Iss. 1, pp. 22-35
Closed Access | Times Cited: 51
New Drug Treatments for Schizophrenia: A Review of Approaches to Target Circuit Dysfunction
Oliver Howes, Eleanor Dawkins, Maria Lobo, et al.
Biological Psychiatry (2024) Vol. 96, Iss. 8, pp. 638-650
Open Access | Times Cited: 17
Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders
Els F. Halff, Grazia Rutigliano, Anna Garcia-Hidalgo, et al.
Trends in Neurosciences (2022) Vol. 46, Iss. 1, pp. 60-74
Open Access | Times Cited: 60
Recognition of methamphetamine and other amines by trace amine receptor TAAR1
Heng Liu, You Zheng, Yue Wang, et al.
Nature (2023) Vol. 624, Iss. 7992, pp. 663-671
Closed Access | Times Cited: 36
Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia
Eric D. Achtyes, Seth C. Hopkins, Nina Dedic, et al.
European Archives of Psychiatry and Clinical Neuroscience (2023) Vol. 273, Iss. 7, pp. 1543-1556
Open Access | Times Cited: 30
Beyond dopamine: Novel strategies for schizophrenia treatment
Paulina Dudzik, Klaudia Lustyk, Karolina Pytka
Medicinal Research Reviews (2024) Vol. 44, Iss. 5, pp. 2307-2330
Closed Access | Times Cited: 13
TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding
Nina Dedic, Lien Wang, Éva Hajós‐Korcsok, et al.
Molecular Metabolism (2024) Vol. 80, pp. 101883-101883
Open Access | Times Cited: 8
Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data
Spyridon Siafis, Virginia Chiocchia, Malcolm Macleod, et al.
Wellcome Open Research (2024) Vol. 9, pp. 182-182
Open Access | Times Cited: 8
AlphaFold accelerated discovery of psychotropic agonists targeting the trace amine–associated receptor 1
Alejandro Díaz‐Holguín, Marcus Saarinen, Duc Duy Vo, et al.
Science Advances (2024) Vol. 10, Iss. 32
Open Access | Times Cited: 8
In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics
Richard Ågren, Nibal Betari, Marcus Saarinen, et al.
The International Journal of Neuropsychopharmacology (2023) Vol. 26, Iss. 9, pp. 599-606
Open Access | Times Cited: 12
TAAR1 as an emerging target for the treatment of psychiatric disorders
Jianfeng Liu, Ruyan Wu, Jun‐Xu Li
Pharmacology & Therapeutics (2023) Vol. 253, pp. 108580-108580
Closed Access | Times Cited: 12
Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders
Savelii R. Kuvarzin, Ilya Sukhanov, Kirill Onokhin, et al.
Biomedicines (2023) Vol. 11, Iss. 7, pp. 1977-1977
Open Access | Times Cited: 11
The role of rodent behavioral models of schizophrenia in the ongoing search for novel antipsychotics
Hugo Cano-Ramírez, Kurt L. Hoffman
Expert Opinion on Drug Discovery (2025), pp. 1-15
Closed Access
Trace amine-associated receptors (TAARs)2-9 knockout mice exhibit reduced wakefulness and disrupted REM sleep
Sunmee Park, Jasmine Heu, Gavin Scheldrup, et al.
Frontiers in Psychiatry (2025) Vol. 15
Open Access
Rational Design of the First Dual Agonist at Trace Amine-Associated Receptor 1 and 5-HT2C Receptors Based on Binding Pocket Similarity for the Treatment of Schizophrenia and Alzheimer’s Disease-Related Psychosis
Jing Lu, Pengfei Yu, Yunjie Wang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Trace amine-associated receptors as potential targets for the treatment of anxiety and depression
Zelong Li, Luoting Wan, Jing Dong, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner
Sung Min Yang, Ayan Ghoshal, Jeffrey M. Hubbard, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 7, pp. 1091-1103
Open Access | Times Cited: 9
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia
Jonathan M. Meyer, Christoph U. Correll
CNS Drugs (2023) Vol. 37, Iss. 7, pp. 545-570
Open Access | Times Cited: 8
Up-regulation of the Trace Amine Receptor, TAAR-1, in the Prefrontal Cortex of Individuals Affected by Schizophrenia
Tiziana Imbriglio, Marika Alborghetti, Valeria Bruno, et al.
Schizophrenia Bulletin (2023) Vol. 50, Iss. 2, pp. 374-381
Closed Access | Times Cited: 7
Unlocking the secrets of trace amine-associated receptor 1 agonists: new horizon in neuropsychiatric treatment
Britto Shajan, Tarun Bastiampillai, Shane D. Hellyer, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 2
Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment
Yunjie Wang, Zhaofeng Liu, Jing Lu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes
Snežana Milanović, Nina Dedic, Robert Lew, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2466-2475
Open Access | Times Cited: 1
Vibrational spectroscopic interpretation, solvent effect and molecular docking studies of TAAR1 partial agonist RO5263397
S. Bushramol, C. Ravikumar
Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy (2024) Vol. 325, pp. 125137-125137
Closed Access | Times Cited: 1
Molecular Docking, Solvent Effect, and Vibrational Spectroscopic Interpretation of Taar1 Partial Agonist Ro5263397
S. Bushramol, C. Ravikumar
(2024)
Closed Access
Multitarget-Directed Ligands Hitting Serotonin Receptors: A Medicinal Chemistry Survey
Imane Ghafir El Idrissi, A. Di Santo, Enza Lacivita, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 9, pp. 1238-1238
Open Access
Page 1 - Next Page

Scroll to top